TY - JOUR T1 - Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol JF - medRxiv DO - 10.1101/2021.03.18.21253888 SP - 2021.03.18.21253888 AU - Louise Sigfrid AU - Thomas M Drake AU - Ellen Pauley AU - Edwin C Jesudason AU - Piero Olliaro AU - Wei Shen Lim AU - Annelise Gillesen AU - Colin Berry AU - David J Lowe AU - Joanne McPeake AU - Nazir Lone AU - Daniel Munblit AU - Anna Casey AU - Peter Bannister AU - Clark D Russell AU - Lynsey Goodwin AU - Antonia Ho AU - Lance Turtle AU - Margret O’Hara AU - Claire Hastie AU - Chloe Donohue AU - Rebecca Spencer AU - Cara Donegan AU - Alison Gummery AU - Janet Harrison AU - Hayley Hardwick AU - Claire E Hastie AU - Gail Carson AU - Laura Merson AU - J Kenneth Baillie AU - Peter JM Openshaw AU - Ewen M Harrison AU - Annemarie B Docherty AU - Malcom G Semple AU - Janet T Scott AU - ISARIC global follow-up working group AU - ISARIC4C investigators Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/23/2021.03.18.21253888.abstract N2 - Objectives The long-term consequences of severe Covid-19 requiring hospital admission are not well characterised. The objective of this study was to establish the long-term effects of Covid-19 following hospitalisation and the impact these may have on patient reported outcome measures.Design A multicentre, prospective cohort study with at least 3 months follow-up of participants admitted to hospital between 5th February 2020 and 5th October 2020.Setting 31 hospitals in the United Kingdom.Participants 327 hospitalised participants discharged alive from hospital with confirmed/high likelihood SARS-CoV-2 infection.Main outcome measures and comparisons The primary outcome was self-reported recovery at least ninety days after initial Covid-19 symptom onset. Secondary outcomes included new symptoms, new or increased disability (Washington group short scale), breathlessness (MRC Dyspnoea scale) and quality of life (EQ5D-5L). We compared these outcome measures across age, comorbidity status and in-hospital Covid-19 severity to identify groups at highest risk of developing long-term difficulties. Multilevel logistic and linear regression models were built to adjust for the effects of patient and centre level risk factors on these outcomes.Results In total 53.7% (443/824) contacted participants responded, yielding 73.8% (327/443) responses with follow-up of 90 days or more from symptom onset. The median time between symptom onset of initial illness and completing the participant questionnaire was 222 days (Interquartile range (IQR) 189 to 269 days). In total, 54.7% (179/327) of participants reported they did not feel fully recovered. Persistent symptoms were reported by 93.3% (305/325) of participants, with fatigue the most common (82.8%, 255/308), followed by breathlessness (53.5%, 175/327). 46.8% (153/327) reported an increase in MRC dyspnoea scale of at least one grade. New or worse disability was reported by 24.2% (79/327) of participants. Overall (EQ5D-5L) summary index was significantly worse at the time of follow-up (median difference 0.1 points on a scale of 0 to 1, IQR: −0.2 to 0.0). Females under the age of 50 years were five times less likely to report feeling recovered (adjusted OR 5.09, 95% CI 1.64 to 15.74), were more likely to have greater disability (adjusted OR 4.22, 95% CI 1.12 to 15.94), twice as likely to report worse fatigue (adjusted OR 2.06, 95% CI 0.81 to 3.31) and seven times more likely to become more breathless (adjusted OR 7.15, 95% CI 2.24 to 22.83) than men of the same age.Conclusions Survivors of Covid-19 experienced long-term symptoms, new disability, increased breathlessness, and reduced quality of life. These findings were present even in young, previously healthy working age adults, and were most common in younger females. Policymakers should fund further research to identify effective treatments for long-Covid and ensure healthcare, social care and welfare support is available for individuals with long-Covid.Section 1: What is already known on this topicLong-term symptoms after hospitalisation for Covid-19 have been reported, but it is not clear what impact this has on quality of life.It is not known which patient groups are most likely to have long-term persistent symptoms following hospitalisation for Covid-19, or if this differs by disease severity.Section 2: What this study addsMore than half of patients reported not being fully recovered 7 months after onset of Covid-19 symptoms.Previously healthy participants and those under the age of 50 had higher odds of worse long-term outcomes compared to older participants and those with comorbidities.Younger women and those with more severe acute disease in-hospital had the worst long-term outcomes.Policy makers need to ensure there is long-term support for people experiencing long-Covid and should plan for lasting long-term population morbidity. Funding for research to understand mechanisms underlying long-Covid and identify potential interventions for testing in randomised trials is urgently required.Competing Interest StatementMalcolm G Semple reports the following Conflict interest: Research Grants from the following entities: National Institute for Health Research (NIHR) [award CO-CIN-01]. Medical Research Council [grant MC_PC_19059]. NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [award 200907] Funding StatementFunding statement: This work is supported by grants from: the National Institute for Health Research (NIHR) [award CO-CIN-01], the Medical Research Council [grant MC_PC_19059], the Imperial Biomedical Research Centre (NIHR Imperial BRC, grant P45058), the Health Protection Research Unit (HPRU) in Respiratory Infections at Imperial College London and NIHR HPRU in Emerging and Zoonotic Infections at University of Liverpool, both in partnership with Public Health England, [NIHR award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135], and Liverpool Experimental Cancer Medicine Centre (Grant Reference: C18616/A25153), NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013], EU Platform for European Preparedness Against (Re-) emerging Epidemics 1 [FP7 project 602525] and NIHR Clinical Research Network for providing infrastructure support for this research. LT is a Wellcome Trust clinical career development fellow, supported by grant number 205228/Z/16/Z. This research was funded in part, by the Wellcome Trust. PJMO is supported by a NIHR Senior Investigator Award [award 201385]. The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, the Wellcome Trust or PHE. Role of the funder: The study sponsors and funders had no role in the study design, collection, analysis, interpretation of data, writing of the report, or the decision to submit the article for publication. Investigators were independent from funders and the authors have full access to all of the data, including any statistical analysis and tables. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given by the South Central - Oxford C Research Ethics Committee in England (ref 13/SC/0149) and the Scotland A Research Ethics Committee (ref 20/SS/0028).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available for reuse through a secure data sharing platform. Access is welcome through the ISARIC Independent Data and Material Access Committee (https://isaric4c.net). https://isaric4c.net ER -